Loading...
Please wait, while we are loading the content...
Etoposide and Idarubicin in a Modified CHOP-Like Regimen (VICED) for Aggressive Non-Hodgkin's Lymphomas
| Content Provider | Scilit |
|---|---|
| Author | D'arco, Alfonso Renzo, Amalia De Notaro, Rosario Pezzullo, Luca Pagnini, Da Vide Pettinato, Guido Rotoli, Bruno |
| Copyright Year | 1998 |
| Description | The superiority of intensive versus standard chemotherapy for aggressive (I: intermediate; H: high grade) NHL is still debated; increased antitumor activity may be counterbalanced by increased toxicity. We have designed a first-line five-drug regimen (yincristine, idarubicin. cyclophosphamide, etoposide and deflazacort), with the aim of potentiating the CHOP protocol without losing tolerability and ease of administration. Seventy-one patients (33% aged × 65) entered the study. CR was obtained in 66.7% of patients (I: 74%; H: 56%), PR in 19.7%: overall response rate was 86.4%. Six patients were resistant, two died during treatment. With a median follow up of two years, relapse has occurred in 14 patients (8 I, 6 H). At 3 years, overall survival was projected to be 62.5% (I 73.5%; H 31.4%), disease free survival 66% (I 71%, H 56.3%). No organ toxicity occurred. Myelosuppression was moderate, with a nadir on the 14th day. Febrile episodes occurred in 16% of courses, dose delay in 19% of courses; dose reduction in 3% of patients. No patient required hospitalization. G-CSF was only occasionally used. This regimen has shown a potent antitumor effect with an excellent tolerance, even in elderly patients. |
| Related Links | http://www.tandfonline.com/doi/pdf/10.3109/10428199809050938 |
| Ending Page | 162 |
| Page Count | 10 |
| Starting Page | 153 |
| ISSN | 10428194 |
| e-ISSN | 10292403 |
| DOI | 10.3109/10428199809050938 |
| Journal | Leukemia & Lymphoma |
| Issue Number | 1-2 |
| Volume Number | 30 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 1998-01-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Leukemia & Lymphoma Oncology Treatment Toxicity Survival Tolerability Antitumor Etoposide Chop Aggressive Courses Idarubicin |
| Content Type | Text |
| Resource Type | Article |
| Subject | Hematology Cancer Research Oncology |
